The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

This week, the FDA is expected to release its approval decision for the non-opioid painkiller made by Vertex Pharmaceuticals Inc. The company that can capture the pain medicine market could hit a ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported fourth-quarter profit of $913 million. The Boston-based company said it had net income of $3.50 per share.

Journavx, then, may serve as a proving point for Vertex. The Boston-based biotechnology company has grown to an almost $115 billion valuation by selling big-ticket medicines for uncommon diseases ...

BOSTON, February 18, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle ...

The Boston, Massachusetts-based drugmaker developed Casgevy with Swiss-American firm CRISPR Therapeutics. Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is ...

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and ...